Dr. Younis Bhat

Scientist, Karolinska Institute, Sweden

Dr. Younis’s research focus is to understand cancer biology by employing protein-centric approaches. He is currently working as a scientist in Pär Nordlund’s group at Karolinska Institute, Sweden. His research group has a distinction of inventing cellular thermal shift assay (CETSA) technology to investigate cellular protein-ligand interactions that is widely used now to understand protein-drug interactions, identification of potential drug targets and dissecting drug resistance mechanisms in response to spectrum of anti-cancer drugs. Dr. Younis employ’s CETSA to study thermal shifts of proteins in response to several anti-cancer drugs. Moreover, Younis integrates other omics approaches such as global proteomics, phosphoproteomics and glycoproteomics to unravel dysregulation of key cellular processes and biological pathways responsible for cancer progression and metastasis. Before joining Pär Nordlund’s group at KI, Younis carried out his doctoral studies at Institute of Bioinformatics (IOB) Bangalore, India where he investigated dysregulation of miRNAs and their cognate protein targets in response to cigarette smoke and chewing tobacco in oral squamous cell carcinoma. Dr. Younis has identified some novel miRNAs and their high confidant protein targets that can potentially be used for early diagnosis and habit specific treatment modalities in case of oral cancer patients.